EBOVAC2 logo

Between them the EBOVAC1 and EBOVAC2 projects are assessing, through clinical trials in Europe and Africa, the safety and tolerability of the two-dose Ebola vaccine regimen, in which patients are first given a dose to prime the immune system, and then a boost dose which is intended to enhance the immune response over time. These trials are contributing to efforts to ensure that future outbreaks of Ebola can be tackled effectively.

More information on Phase 2 is available on the EBOVAC2 website.

These projects have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations (EFPIA).
Copyright © 2023 Ebovac | Terms and Conditions | WordPress development by Toast.